糖尿病黄斑水肿玻璃体腔注射贝伐珠单抗、阿柏西普或雷珠单抗后血浆血管内皮生长因子水平的变化
研究评估72例糖尿病视网膜病变患者血浆血管内皮生长因子水平与病情严重程度的相关性,并观察42例糖尿病黄斑水肿患者初次注射贝伐珠单抗、阿柏西普或雷珠单抗后的变化。结果显示基线血浆血管内皮生长因子与糖尿病黄斑水肿或糖尿病视网膜病变严重程度无相关性;贝伐珠单抗和阿柏西普显著降低血浆血管内皮生长因子达4周,雷珠单抗无此效应。
要点
- 基线血浆血管内皮生长因子水平与糖尿病黄斑水肿或糖尿病视网膜病变严重程度无相关性。
- 贝伐珠单抗组血浆血管内皮生长因子从51.9 pg/mL降至1周11.9 pg/mL、4周24.1 pg/mL(P=0.0130和0.0201)。
- 阿柏西普组从52.2 pg/mL降至7.8 pg/mL和12.6 pg/mL(均P<0.001),雷珠单抗组无此降低。
核心结论
- 基线血浆血管内皮生长因子水平与糖尿病视网膜病变或糖尿病黄斑水肿严重程度无相关性。
- 玻璃体腔注射贝伐珠单抗或阿柏西普显著降低血浆血管内皮生长因子达4周,雷珠单抗无此效应。
- 血浆血管内皮生长因子水平变化似乎在糖尿病黄斑水肿或糖尿病视网膜病变的进展或治疗中不关键。
研究设计与样本
- 研究评估72例糖尿病视网膜病变患者的血浆血管内皮生长因子水平,并测量42例糖尿病黄斑水肿患者初次接受贝伐珠单抗、阿柏西普或雷珠单抗玻璃体腔注射后的变化。
主要发现
- 血浆血管内皮生长因子水平与糖尿病黄斑水肿或糖尿病视网膜病变严重程度无相关性。
- 贝伐珠单抗组基线血浆血管内皮生长因子51.9 pg/mL,1周降至11.9 pg/mL(P=0.0130),4周降至24.1 pg/mL(P=0.0201)。
- 阿柏西普组基线血浆血管内皮生长因子52.2 pg/mL,1周降至7.8 pg/mL、4周降至12.6 pg/mL(均P<0.001)。
- 雷珠单抗组未观察到血浆血管内皮生长因子降低。
关键数值与推荐
- 贝伐珠单抗组血浆血管内皮生长因子从51.9 pg/mL降至1周11.9 pg/mL和4周24.1 pg/mL(P=0.0130和0.0201)。
- 阿柏西普组从52.2 pg/mL降至1周7.8 pg/mL和4周12.6 pg/mL(均P<0.001)。
- 雷珠单抗组无血浆血管内皮生长因子降低。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The aim of this study was to investigate the changes in plasma vascular endothelial growth factor (VEGF) level depending on the severity of diabetic retinopathy (DR) or diabetic macular edema (DME) and after intravitreal injection of bevacizumab, aflibercept, or ranibizumab for treatment of DME. METHODS: Plasma VEGF level was evaluated in 72 patients with DR and changes were measured in 42 patients with DME receiving intravitreal injections of bevacizumab, aflibercept, or ranibizumab at the initial injection. RESULTS: There were no correlations between plasma VEGF level and the severity of DME or DR. Baseline plasma VEGF level (51.9 pg/mL) was significantly reduced using bevacizumab to 11.9 pg/mL after 1 week and 24.1 pg/mL after 4 weeks (P = 0.0130 and 0.0201, respectively). In aflibercept-treated eyes, plasma VEGF decreased from 52.2 pg/mL to 7.8 pg/mL and 12.6 pg/mL, respectively, at the same time points (both P < 0.001). No such reductions were observed in patients receiving ranibizumab. CONCLUSION: Baseline plasma VEGF level showed no correlations with DR or DME severity, whereas intravitreal injection of bevacizumab or aflibercept significantly reduced plasma VEGF for up to 4 weeks and ranibizumab produced no such effects. Changes in plasma VEGF level seemed not to be critical in progression or treatment of DME and DR.
引用
- Hirano T, Toriyama Y, Iesato Y, et al. CHANGES IN PLASMA VASCULAR ENDOTHELIAL GROWTH FACTOR LEVEL AFTER INTRAVITREAL INJECTION OF BEVACIZUMAB, AFLIBERCEPT, OR RANIBIZUMAB FOR DIABETIC MACULAR EDEMA. Retina. 2018. PMID: 29280940. doi:10.1097/IAE.0000000000002004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。